Pharmacyclics

Investor's Business Daily

• Pharmacyclics (PCYC) fell 10.5% to 51.33 on negative data on its experimental cancer drug ibrutinib. The company said a small group of multiple myeloma patients did not experience tumor shrinkage after treatment with the drug, under development in partnership with Johnson & Johnson (JNJ). Pharmacyclics also posted better-than-expected fiscal Q1 results.

View Comments (0)